Naltrexone/bupropion for binge-eating disorder: A human laboratory investigation of mechanisms
This human laboratory investigation support and extend the findings of the RCT. NB may reduce weight in patients with BED by reducing calories consumed during eating episodes of highly preferred high-caloric food. Further, results identified reduced craving and hunger ratings as potential markers of early treatment response.
Authors
- Meaghan Lavery
- Carlos M. Grilo (ORCID: https://orcid.org/0000-0003-0245-3444)
- Ralph Dileone (ORCID: https://orcid.org/0000-0002-4770-2590)
- Brian P. Pittman
- Sherry A. McKee
- Janet A. Lydecker
- Ania M. Jastreboff
Institutions
- Yale University (US)
Publication Details
- Journal
- Drug and Alcohol Dependence Reports
- Published
- 2026-03-11
- DOI
- https://doi.org/10.1016/j.dadr.2026.100428
- Primary Topic
- Eating Disorders and Behaviors
- Type
- article
- Field-Weighted Citation Impact
- 0.00